Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database

References

• Jones MP, Nicholl D, Trakas K. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther. 2010;48(6):383–399.
   PubMed Web of Science ®Google Scholar
• He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995;10(1):19–30.
   PubMed Web of Science ®Google Scholar
• Gilday E, Nasrallah HA. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Recent Clin Trials. 2012;7(1):2–9.
   PubMedGoogle Scholar
• Eltze M. In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996;295(1):69–73.
   PubMed Web of Science ®Google Scholar
• Samtani MN, Gopal S, Gassmann-Mayer C, et al. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25(10):1–45.
   Web of Science ®Google Scholar
• Cleton A, Rossenu S, Crauwels H, et al. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. J Clin Pharmacol. 2014;54(9):1048–1057.
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough D, Karcher K, et al. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials. J Clin Psychopharmacol. 2013;33(2):157–161.
   PubMed Web of Science ®Google Scholar
• Pierce P, Gopal S, Savitz A, et al. Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia. Curr Med Res Opin. 2016;32(10):1671–1679.
   PubMed Web of Science ®Google Scholar
• Tsay ME, Klein-Schwartz W, Anderson B. Toxicity and clinical outcomes of paliperidone exposures reported to U.S. Poison Centers. Clin Toxicol. 2014;52(3):207–213.
   Web of Science ®Google Scholar
• Drevin G, Ripault B, Ballot-Ragaru J-B, et al. Death following an intramuscular injection of paliperidone: a case report. Toxicol Anal Clin. 2020;32(2):132–136.
   Web of Science ®Google Scholar
• Moore N, Noblet C, Kreft-Jais C, et al. [French pharmacovigilance database system: examples of utilisation]. Therapie. 1995;50(6):557–562.
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
   PubMed Web of Science ®Google Scholar
• WHOCC – ATC/DDD Index [Internet]; [cited 2020 Aug 20]. Available from: https://www.whocc.no/atc_ddd_index/.
   Google Scholar
• Mauri MC, Reggiori A, Paletta S, et al. Paliperidone for the treatment of schizophrenia and schizoaffective disorders – a drug safety evaluation. Expert Opin Drug Saf. 2017;16(3):365–379.
   PubMed Web of Science ®Google Scholar
• Misawa F, Kishimoto T, Hagi K, et al. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2–3):220–230.
   PubMed Web of Science ®Google Scholar
• Pappa S, Mason K, Howard E. Long-term effects of paliperidone palmitate on hospital stay and treatment continuation. Int Clin Psychopharmacol. 2019;34(6):305–311.
   PubMed Web of Science ®Google Scholar
• Poloni N, Ielmini M, Caselli I, et al. Oral antipsychotic versus long-acting injections antipsychotic in schizophrenia spectrum disorder: a mirror analysis in a real-world clinical setting. Psychopharmacol Bull. 2019;49(2):17–27.
   PubMedGoogle Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. int J Neuropsychopharmacol. 2016;19(7):pyw018.
   PubMed Web of Science ®Google Scholar
• Morris MT, Tarpada SP. Long-acting injectable paliperidone palmitate: a review of efficacy and Safety. Psychopharmacol Bull. 2017;47(2):42–52.
   PubMedGoogle Scholar
• Mathews M, Pei H, Savitz A, et al. Paliperidone palmitate 3-monthly versus 1-monthly injectable in patients with schizophrenia with or without prior exposure to oral risperidone or paliperidone: a post hoc, subgroup analysis. Clin Drug Investig. 2018;38(8):695–702.
   PubMed Web of Science ®Google Scholar
• Emond B, Khoury ACE, Patel C, et al. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans. Curr Med Res Opin. 2019;35(3):407–416.
   PubMed Web of Science ®Google Scholar
• Li KJ, Greenstein AP, Delisi LE. Sudden death in schizophrenia. Curr Opin Psychiatry. 2018;31(3):169–175.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Watkins J. Prolactin elevations and permeability glycoprotein. |Prim Care Companion. Prim Care Companion CNS Disord. 2019;21(3):0–0.
   Google Scholar
• Vuk A, Rojnic Kuzman M, Baretic M, et al. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature. Psychiat Danub. 2017;29(2):121–135.
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophrenia Res. 2010;116(2–3):107–117.
   PubMed Web of Science ®Google Scholar
• Coppola D, Liu Y, Gopal S, et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry. 2012;12:26.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):9–62.
   PubMed Web of Science ®Google Scholar
• Schulz M, Schmoldt A, Andresen-Streichert H, et al. Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care. 2020;24(1):195.
   PubMed Web of Science ®Google Scholar
• Ravenstijn P, Remmerie B, Savitz A, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330–339.
   PubMed Web of Science ®Google Scholar
• Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585–600.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Neyens M, De Meulder M, et al. Population pharmacokinetics of paliperidone palmitate (once-monthly formulation) in Japanese, Korean, and Taiwanese patients with schizophrenia. Clin Pharmacol Drug Dev. 2020;9(2):224–234.
   PubMed Web of Science ®Google Scholar
• Yin J, Collier AC, Barr AM, et al. Paliperidone palmitate long-acting injectable given intramuscularly in the deltoid versus the gluteal muscle: are they therapeutically equivalent? J Clin Psychopharmacol. 2015;35(4):447–449.
   PubMed Web of Science ®Google Scholar
• Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9(5):410–418.
   PubMed Web of Science ®Google Scholar
• Su Y-A, Bousman C, Li Q, et al. Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia. J Neural Transm. 2019;126(1):19–25.
   PubMed Web of Science ®Google Scholar
• Li Q, Wineinger NE, Fu D-J, et al. Genome-wide association study of paliperidone efficacy. Pharmacogenet Genom. 2017;27(1):7–18.
   PubMed Web of Science ®Google Scholar
• Hoffman RS. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol. 2007;45(8):943–945.
   PubMed Web of Science ®Google Scholar